The liver disease treatment market size is projected to reach US$ 6.94 billion by 2031 from US$ 4.41 billion in 2023. The market is expected to register a CAGR of 5.8% during 2023–2031. Increasing use of hybrid systems for imaging owing to the benefits offered as compared to the conventional systems are likely to remain key trends in the market.
Liver disease treatment market is driven by the increasing prevalence of liver diseases along with surge in technological advancement for the treatment and diagnosis of such conditions. There have been various factors contributing to the increasing prevalence of liver disease, increased consumption of alcohol, surging liver infections such as hepatitis A and B, and increasing incidence of liver cancer, and others. Additionally, surging collaborations and partnerships among market players for the development of new treatment and diagnostic techniques are expected to further contribute to the overall market growth.
Liver disease treatment market is expected to grow moderately during the forecast period owing to the rising prevalence of liver diseases and technological advancements in imaging techniques. Additionally, surging collaboration and partnership among market players is likely to create ample opportunities however, the high cost of imaging techniques and stringent regulatory policies are expected to hamper the market growth. Furthermore, North America accounts for the major share followed by Europe, and Asia Pacific is expected to show significant growth over the next few years. North America consists of high developed countries with developed healthcare infrastructure along with high disposable income. Asia Pacific consists of developing countries with and increasing number of liver disease cases, government initiatives taken for liver treatment, and a rise in the development by the market players for the treatment of liver diseases. The change in the culture, lifestyle and consumption of alcohol is expected to increase the number of liver diseases number and eventually the market for liver treatment is anticipated to grow significantly.
There has been a significant rise in the number of liver diseases across the globe during the previous years. Various factors such as changing lifestyle patterns, diabetes, obesity, metabolic syndrome, and cardiovascular disorders have been leading to an increase in the cases of liver disease. According to National institute of Health, 2023 report, Liver disease accounts for 2 million deaths annually which is 4% of all deaths globally. Among various liver diseases, the cases of Alcoholic liver disease (ALD) is among the main causes of chronic liver disease worldwide. ALC accounts for 48% of cirrhosis associated deaths in the United States. Liver disease is considered to be the fifth reason cause of death in England & Wales, after heart, cancer, stroke and respiratory disease. Alcohol consumption is said to be a major factor leading to liver diseases among the population in the United States as well as UK. In the UK, alcohol consumption per person across the population has more than doubled in the last half-century. The rise in the number of liver diseases is expected to grow at a significant rate during the forecast period, hence fueling the growth of the market in the coming years.
In recent years, there have been various partnerships as well as collaborations among the players operating in the market. For instance, in January, 2024, Mindray North America, collaborated with Aegle Medical Solutions, to be the sole distributor of its Hepatus-Series Transient Elastography Diagnostic Ultrasound Systems for liver care. Additionally, in December 2023, Clarivate Plc launched VeriSIM Life Translational Index on Cortellis Drug Discovery Intelligence and this new solution is the next step of an intensifying partnership between Clarivate and VeriSIM Life. The integrated workflow provides customers with a multitude of predictive compound safety and efficacy insights, including bioavailability, hepatic and renal clearance, clinical toxicity, first-in-human dose and more. Partnerships and collaborations are considered to offer growth opportunities to the market players. Such growth strategies made by the companies are likely to offer significant growth opportunities for the market players operating in the liver treatment market during the forecast period.
Key segments that contributed to the derivation of the liver disease treatment market analysis are disease and imaging modality.
The geographic scope of the liver disease treatment market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.
North America has dominated the market owing to the increasing incidences of hepatitis A, B and C, rise in the number of the liver cancer and nonalcoholic fatty liver diseases. The developments by the market players for the diagnostic imaging equipment and rise in the market consolidation are likely to lead the growth of the liver disease treatment market in the forecast period. In addition, the growth of the medical tourism is the Mexico is attracting more patients for the treatments at cheaper cost. The region is anticipated to continue to hold largest market for the liver treatment in the coming near future. Asia Pacific is anticipated to grow with the highest CAGR in the coming years.
The regional trends and factors influencing the Liver Disease Treatment Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Liver Disease Treatment Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ 4.41 Billion |
| Market Size by 2031 | US$ 6.94 Billion |
| Global CAGR (2023 - 2031) | 5.8% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2031 |
| Segments Covered |
By Diseases
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The Liver Disease Treatment Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Liver Disease Treatment Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The liver disease treatment market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the liver disease treatment market are listed below:
The “Liver Disease Treatment Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:
North America Region is expected to dominate the liver disease treatment market in 2023.
The increasing prevalence of liver diseases and technological advancement in imaging techniques are the driving factors impacting the liver disease treatment market
Increasing use of hybrid systems for imaging over conventional systems are future trends of liver disease treatment market
Leading market players operating in the liver disease treatment market include General Electric, Koninklijke Philips N.V., Siemens AG, Canon Medical Systems Corporation, Hitachi, Ltd, Elekta AB (pub), Neusoft Corporation, Samsung Healthcare, BPL Medical Technologies, and Cura Healthcare.
The liver disease treatment market is expected to reach around US$ 6.94 Bn by the end of 2031
The Liver disease treatment is expected to grow at the CAGR of 5.8% during the forecast period.